Clinical trial
Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation…
NCT00350818 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00350818 |
|---|---|
| Title | Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT) |
| Official title | Azacitidine Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for AML and MDS |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Celgene Corporation Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndrome, Leukemia |
| Intervention type | Drug |
| Interventions | Azacitidine |
| Enrollment | 90 |
| Start date | Oct 1, 2005 |
| Primary completion | Aug 1, 2010 |
| Completion | Aug 1, 2010 |
| First posted | Jul 11, 2006 |
| Last update posted | Jul 30, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: